Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes

ClinicalTrials.gov ID: NCT02054897

Public ClinicalTrials.gov record NCT02054897. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 7:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Study identification

NCT ID
NCT02054897
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
388 participants

Conditions and interventions

Interventions

  • placebo Drug
  • semaglutide Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 2, 2014
Primary completion
May 7, 2015
Completion
May 7, 2015
Last update posted
Jun 11, 2019

2014 – 2015

United States locations

U.S. sites
38
U.S. states
18
U.S. cities
33
Facility City State ZIP Site status
Novo Nordisk Investigational Site Anniston Alabama 36207
Novo Nordisk Investigational Site Birmingham Alabama 35216
Novo Nordisk Investigational Site Pell City Alabama 35128
Novo Nordisk Investigational Site Hawaiian Gardens California 90716
Novo Nordisk Investigational Site Lomita California 90717
Novo Nordisk Investigational Site Los Angeles California 90057
Novo Nordisk Investigational Site Montclair California 91763
Novo Nordisk Investigational Site Northridge California 91324
Novo Nordisk Investigational Site Colorado Springs Colorado 80920
Novo Nordisk Investigational Site Boynton Beach Florida 33472
Novo Nordisk Investigational Site Jacksonville Florida 32277
Novo Nordisk Investigational Site Miami Florida 33015
Novo Nordisk Investigational Site Miami Florida 33143
Novo Nordisk Investigational Site Miami Florida 33144
Novo Nordisk Investigational Site Miami Florida 33173
Novo Nordisk Investigational Site Miami Florida 33174
Novo Nordisk Investigational Site Miami Lakes Florida 33016
Novo Nordisk Investigational Site Pembroke Pines Florida 33026
Novo Nordisk Investigational Site Savannah Georgia 31406
Novo Nordisk Investigational Site Brownsburg Indiana 46112
Novo Nordisk Investigational Site Franklin Indiana 46131
Novo Nordisk Investigational Site Wichita Kansas 67226
Novo Nordisk Investigational Site Lexington Kentucky 40504
Novo Nordisk Investigational Site Olive Branch Mississippi 38654
Novo Nordisk Investigational Site Billings Montana 59101
Novo Nordisk Investigational Site Omaha Nebraska 68144
Novo Nordisk Investigational Site Belvidere New Jersey 07823
Novo Nordisk Investigational Site Albuquerque New Mexico 87102
Novo Nordisk Investigational Site Charlotte North Carolina 28277
Novo Nordisk Investigational Site Whiteville North Carolina 28472
Novo Nordisk Investigational Site Cincinnati Ohio 45255
Novo Nordisk Investigational Site Delaware Ohio 43015
Novo Nordisk Investigational Site Levittown Pennsylvania 19056
Novo Nordisk Investigational Site Spartanburg South Carolina 29303
Novo Nordisk Investigational Site Dallas Texas 75230
Novo Nordisk Investigational Site Sealy Texas 77474
Novo Nordisk Investigational Site Sugar Land Texas 77478
Novo Nordisk Investigational Site Sugar Land Texas 77479

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 48 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02054897, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 11, 2019 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02054897 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →